Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3–ABCB1 Signaling in Hepatocellular Carcinoma
Top Cited Papers
Open Access
- 6 September 2022
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (20) , 3845-3857
Abstract
Lenvatinib is an inhibitor of multiple receptor tyrosine kinases that was recently authorized for first-line treatment of hepatocellular carcinoma (HCC). However, the clinical benefits derived from lenvatinib are limited, highlighting the urgent need to understand mechanisms of resistance. We report here that HCC cells develop resistance to lenvatinib by activating EGFR and stimulating the EGFR–STAT3–ABCB1 axis. Lenvatinib resistance was accompanied by aberrant cholesterol metabolism and lipid raft activation. ABCB1 was activated by EGFR in a lipid raft–dependent manner, which significantly enhanced the exocytosis of lenvatinib to mediate resistance. Furthermore, clinical specimens of HCC showed a correlation between the activation of the EGFR–STAT3–ABCB1 pathway and lenvatinib response. Erlotinib, an EGFR inhibitor that has also been shown to inhibit ABCB1, suppressed lenvatinib exocytosis, and combined treatment with lenvatinib and erlotinib demonstrated a significant synergistic effect on HCC both in vitro and in vivo. Taken together, these findings characterize a mechanism of resistance to a first-line treatment for HCC and offer a practical means to circumvent resistance and treat the disease. Significance: HCC cells acquire resistance to lenvatinib by activating the EGFR–STAT3–ABCB1 pathway, identifying combined treatment with erlotinib as a strategy to overcome acquired resistance and improve the clinical benefit of lenvatinib.Keywords
All Related Versions
Funding Information
- National Natural Science Foundation of China (81930074)
- National Natural Science Foundation of China (91959203)
- Program of Shanghai Academic Research Leader (20XD1400900)
This publication has 38 references indexed in Scilit:
- Conformational Coupling across the Plasma Membrane in Activation of the EGF ReceptorCell, 2013
- Lipid Rafts As a Membrane-Organizing PrincipleScience, 2010
- Lattices, rafts, and scaffolds: domain regulation of receptor signaling at the plasma membraneJournal of Cell Biology, 2009
- The Epidermal Growth Factor Receptor Pathway: A Model for Targeted TherapyClinical Cancer Research, 2006
- Rafts defined: a report on the Keystone symposium on lipid rafts and cell functionJournal of Lipid Research, 2006
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- Erlotinib hydrochlorideNature Reviews Drug Discovery, 2005
- The discovery of receptor tyrosine kinases: targets for cancer therapyNature Reviews Cancer, 2004
- Ligand-Independent Oncogenic Transformation by the EGF Receptor Requires Kinase Domain Catalytic ActivityExperimental Cell Research, 2002
- Localization of Epidermal Growth Factor-stimulated Ras/Raf-1 Interaction to Caveolae MembraneJournal of Biological Chemistry, 1996